SIOC English
化学学报
高级检索

化学学报 >

2012 , Vol. 70 >Issue 02: 161 - 169

DOI: https://doi.org/10.6023/A1105183

研究论文

“右旋糖酐-磁性层状复合氢氧化物-氟尿嘧啶”给药系统的超分子组装表征与急毒性水平

  • 苟国敬 ,
  • 王志宇 ,
  • 刘彦红 ,
  • 薛冰 ,
  • 黄洁 ,
  • 孙岳
展开
  • a 宁夏医科大学医用化学系 银川 750004;
    b 宁夏医科大学医学科学技术研究中心 银川 750004

收稿日期: 2011-05-18

  修回日期: 2011-09-28

  网络出版日期: 2012-02-25

基金资助

国家自然科学基金(No.20961008);宁夏高等学校科学技术研究重点项目基金(No.200919341);宁夏自然科学基金(No.NZ09102);教育部科学技术研究重点项目基金(No.207127)资助项目.

收起

Supra-molecular Assembly Characterization and Urgent Toxic Level of "Dextran-Magnetic Layered Double Hydroxide-Fluorouracil" Drug Delivery System

  • GOU Guo-Jing ,
  • WANG Zhi-Yu ,
  • LIU Yan-Hong ,
  • XUE Bing ,
  • HUANG Jie ,
  • SUN Yue
Expand
  • a Department of Chemistry, Ningxia Medical University, Yinchuan 750004;
    b Research Center of Medical Science and Technology, Ningxia Medical University, Yinchuan 750004

Received date: 2011-05-18

  Revised date: 2011-09-28

  Online published: 2012-02-25

Supported by

Project supported by the National Natural Science Foundation of China (No.20961008);Ningxia Higher School Science and Technology Research Key Project Fund (No.200919341);Ningxia Natural Science Fund (No.NZ09102);Ministry of Education Science and Technology Research Key Project Fund (No.207127).

Fold

摘要

用“前体共沉淀-离子交换插层-原位复合-溶剂转换”技术合成“右旋糖酐-磁性层状复合氢氧化物-氟尿嘧啶”(DET-MLDH-FU, DMF) 运载系统, 通过XRD, IR, TEM, TG 表征及体外释放实验研究了DMF的物相特征与缓释性能, 通过对小鼠灌胃和腹腔注射给药考察了DMF 与载体MLDH 的急毒性水平. 结果表明, DMF 等超分子的XRD 与R-六 方LDH 衍射特征相符, 是Fe3.6Fe0.9(O,OH,Cl)9 型LDH 及微量Fe3O4 的复合晶相, DMF 具有DET, MLDH 与FU 分级组装形成的核壳式构造. 体外pH 7.35 PBS 溶出介质中, DMF 的药物释放遵守零级模型C-1.162×10-5=4.566×10-7t,速率常数4.566×10-7 mol-1·L·m-1. DMF, MLDH-FU 及MLDH 可经正常代谢排出体外, 口服毒性小; 腹腔注射DMF的LD50为2542.8 mg·kg-1, MLDH 的LD50 为1951.0 mg·kg-1, 均属低毒性物质. DET 的复合组装对Fe(Ⅱ, Ⅲ)LDH 构架有抗氧化保护作用, 对不同MLDH-FU 粒子进行选择、分离与包封, 提高MLDH-FU 的缓释效果、强化MLDH 的控释性能, 降低给药系统DMF 的急毒性水平.

关键词： 右旋糖酐-磁性层状复合氢氧化物-氟尿嘧啶给药系统; 三级超分子组装; 药物释放模型; 急毒性水平

本文引用格式

苟国敬 , 王志宇 , 刘彦红 , 薛冰 , 黄洁 , 孙岳 . “右旋糖酐-磁性层状复合氢氧化物-氟尿嘧啶”给药系统的超分子组装表征与急毒性水平[J]. 化学学报, 2012 , 70(02) : 161 -169 . DOI: 10.6023/A1105183

Abstract

The drug delivery system DMF with a formation of DET-MLDH-FU (dextran-magnetic layered double hydroxide-fluorouracil) was synthesized by the “precursor co-precipitation-intercalated assembly with ion exchange-dextran in situ composite-solvent conversion” technology, the crystal-phase characteristic and slow-release performance of DMF system were investigated through XRD, IR, TEM, TG characterization and dissolve out experiment in vitro. The urgent toxic levels of DMF and MLDH were inspected through mice animal experiments of irrigation stomach and intraperitoneal injection. The results showed that the XRD of DMF, MLDH-FU and MLDH matched with R-sixtetragonum LDH series, mixed by Fe3.6Fe0.9(O,OH,Cl)9 type crystal-phase and trace iron oxide. The DMF supra-molecular system consisted by DET, MLDH and FU components had a core-shell structure formed through grading assembly. The drug release model of DMF accorded with the zero-order kinetics equation C-1.162×10-5=4.566×10-7t at pH 7.35 of PBS in vitro, and its rate constant was 4.566×10-7 mol-1·L·m-1. DMF, MLDH-FU and MLDH could be excreted in vivo through normal metabolism, with a tiny oral toxicity. The LD50 of intraperitoneal injection experiment were 2542.8 mg·kg-1 and 1951.0 mg·kg-1 respectively for DMF and MLDH-FU, which meant all belonged to low toxic substances. Composite assembly with DET produced the antioxidant protection function for the layered structure of MLDH-FU, resulting in selection, separation and encapsulation of different particles, and gave rise to improving for the slow-release effect of MLDH-FU, strengthening of controlled-release characteristic for MLDH, and reducing of the urgent toxic levels for DMF drug delivery system.

Key words： dextran-magnetic layered double hydroxide-fluorouracil (DET-MLDH-FU) drug delivery system; three-level supra-molecular assembly; the drug release model; urgent toxic level

参考文献

1 Gou, G.-J.; Bao, F.-J.; Yang, J.-H. CN 101607088A, 2009 [Inv p gaz. 2009, 1241, 139] (in Chinese). (苟国敬, 鲍凤娟, 杨建宏, 发明专利公报, 101607088A, 2009, 1241, 139.)

2 Gou, G.-J.; Bao, F.-J.; Jiang, Y.-X. CN 101607091B, 2009 [Inv p gaz. 2009, 1241, 140] (in Chinese). (苟国敬, 鲍凤娟, 蒋袁絮, 发明专利公报, 101607091A, 2009, 1241, 140.)

3 Choi, H. J.; Kwon, T. M.; Jhon, M. S. J. Mater. Sci. 2000, 35, 889.  

4 Kwon, T.; Tsigdinos, G. Α.; Pinnavaia, T. J. Am. Chem. Soc. 1988, 110, 3653.  

5 Dimotakis, E. D.; Pinnavaia, T. J. Inorg. Chem. 1990, 29, 2393.  

6 Li, S. P. Colloids Surf. A 2006, 290, 56.  

7 Wang, J.-Q.; Li, X.; Li, S.-P. Acta Chim. Sinica 2011, 69, 137 (in Chinese). (王继芹, 李鑫, 李淑萍, 化学学报, 2011, 69, 137.)

8 Gou, G.-J.; Xu, H.-P.; Liu, J.-P. Acta Chim. Sinica 2009, 67, 65 (in Chinese). (苟国敬, 许红平, 刘建平, 化学学报, 2009, 67, 65.)

9 Xing, F.-F.; Ni, Z.-M.; Wang, P. Acta Chim. Sinica 2007, 65, 2738 (in Chinese). (邢方方, 倪哲明, 王平, 化学学报, 2007, 65, 2738.)

10 Jin, S.; Fallgren, P. H.; Morris, J. M. Sci. Technol. Adv. Mater. 2007, 8, 67.  

11 Josanlet, C. V.; Oscar, H. G.; Kate, L.; Steven, L. S. Inorg. Chem. 2003, 42, 5621.  

12 Urs, O. H.; Judy, S. R.; Linda, H. S.; Anita, C. B.; Framin, M.; James, P. D.; David, B. Mol. Pharmaceutics 2009, 6, 1417.  

13 Bao, F.-J.; Gou, G.-J.; Wang, S.-J. Chin. Pharm. J. 2011, 46, 128 (in Chinese). (鲍凤娟, 苟国敬, 王淑静, 中国药学杂志, 2011, 46, 128.)

14 Bao, F.-J. M.S. Thesis Ningxia Medical University, Yinchuan, 2010 (in Chinese). (鲍凤娟, 硕士论文, 宁夏医科大学, 银川, 2010.)  

15 Shi, J.-H.; Wu, X.-T.; Fan, M.-X.; Jiang, G.-R. Chin. Phys. Med. J. 1995, 17, 71 (in Chinese). (施建华, 吴信陶, 樊明信, 姜光锐, 中华物理医学杂志, 1995, 17, 71.)  

16 Xu, S.-Y.; Chen, X. Pharmacology Experiment Methodology, Science Press, Beijing, 1982, pp. 402～403 (in Chinese). (徐叔云, 陈修, 药理实验方法学, 科学出版社, 北京,  

1982, pp. 402～403.)  

17 Inorganic Chemistry Write Group, Inorganic Chemistry, People's Education Press, Shanghai, 1978, p. 205 (in Chinese). (无机化学编写组, 无机化学, 人民教育出版社, 上海,  

1978, p. 205.)  

18 Gou, G.-J.; Ma, P.-H.; Chu, M.-X. Acta Phys.-Chim. Sin. 2004, 20, 1357 (in Chinese). (苟国敬, 马培华, 褚敏雄, 物理化学学报, 2004, 20, 1357.)

19 Jiao, L.; Gou, G.-J.; Yang, J.-H.; Yang, X.-P. Chin. Pharm. J. 2011, 46, 357 (in Chinese). (焦林, 苟国敬, 杨建宏, 杨晓萍, 中国药学杂志, 2011, 46, 357.)

20 Gou, G.-J.; Bao, F.-J.; Zheng, Z.-X.; Xu, H.-P. Chem. Res. Appl. 2008, 20, 1158 (in Chinese). (苟国敬, 鲍凤娟, 郑志详, 许红平, 化学研究与应用, 2008, 20, 1158.)

21 Ahmet, N. A.; Birgl, Z. K.; Abidin, T.; Vicente, R. Inorg. Chem. 2009, 48, 8871.  

22 Higuchi, T. J. Pharm. Sci. 1963, 52, 1145.  

23 Ambrogi, V.; Fardella, G.; Grandolini, G.; Perioli, L. Int. J. Pharm. 2001, 220, 23.

24 Bao, F.-J.; Wang, S.-J.; Gou, G.-J.; Lu, N.-Q.; Yang, X.-P.; Jiao, L.; Wang, Z.-Y. Chem. Res. Appl. 2010, 22, 47 (in Chinese). (鲍凤娟, 王淑静, 苟国敬, 卢宁清, 杨晓萍, 焦林, 王志 宇, 化学研究与应用, 2010, 22, 47.)

25 Xu, X.-Y. Mod. Prevent Medic. 1997, 24, 246 (in Chinese). (徐新云, 现代预防医学, 1997, 24, 246.)
Options
文章导航

/

〈 〉